Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HEPANASDAQ:NMTRNASDAQ:TCBPNASDAQ:TRVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEPAHepion Pharmaceuticals$0.04-27.0%$0.30$0.05▼$66.00$441K1.91.30 million shs465,035 shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs103 shsTCBPTC Biopharm$0.68-55.8%$0.68$0.50▼$195.20$279K0.01147,050 shs5.33 million shsTRVNTrevena$1.15+2.2%$1.20$0.95▼$10.92$1.10M0.872,151 shs2,166 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEPAHepion Pharmaceuticals0.00%-15.14%-77.16%-98.85%-99.90%NMTR9 Meters Biopharma0.00%0.00%0.00%0.00%+6,463.64%TCBPTC Biopharm0.00%0.00%0.00%-65.43%-99.61%TRVNTrevena0.00%+8.59%-10.16%-31.55%-88.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHEPAHepion Pharmaceuticals0.517 of 5 stars0.05.00.00.00.60.00.6NMTR9 Meters BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ATCBPTC Biopharm1.2673 of 5 stars3.50.00.00.00.00.80.6TRVNTrevenaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHEPAHepion Pharmaceuticals 0.00N/AN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/ATCBPTC Biopharm 3.00Buy$48.006,948.46% UpsideTRVNTrevena 2.00Hold$5.00334.78% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/ANMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ATCBPTC Biopharm$4.76M0.06N/AN/A$519.58 per share0.00TRVNTrevena$443K2.49N/AN/A($11.07) per share-0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%8/11/2025 (Estimated)NMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ATCBPTC Biopharm-$7.35MN/A0.00∞N/AN/AN/AN/AN/ATRVNTrevena-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%8/6/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/ATCBPTC BiopharmN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHEPAHepion PharmaceuticalsN/A1.301.30NMTR9 Meters BiopharmaN/A0.590.59TCBPTC Biopharm0.671.12N/ATRVNTrevenaN/A2.422.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHEPAHepion Pharmaceuticals17.24%NMTR9 Meters Biopharma22.34%TCBPTC Biopharm16.25%TRVNTrevena13.56%Insider OwnershipCompanyInsider OwnershipHEPAHepion Pharmaceuticals4.70%NMTR9 Meters Biopharma2.40%TCBPTC Biopharm15.44%TRVNTrevena2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHEPAHepion Pharmaceuticals2010.98 million6.63 millionNo DataNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataTCBPTC Biopharm80410,00028,000Not OptionableTRVNTrevena40959,000841,000OptionableTCBP, NMTR, TRVN, and HEPA HeadlinesRecent News About These CompaniesTrevena (NASDAQ:TRVN) Coverage Initiated by Analysts at Wall Street ZenMay 24, 2025 | americanbankingnews.comTrevena Enters Securities Exchange Agreement with InvestorMay 15, 2025 | tipranks.comBerks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball winApril 11, 2025 | readingeagle.comVanessa Hudgens and Oliver Trevena Appear at Expo West for CaliwaterMarch 9, 2025 | msn.comJMP Securities downgrades Trevena (TRVN) to a HoldDecember 28, 2024 | markets.businessinsider.com‘Plane’ Actor Oliver Trevena Signs With Untitled EntertainmentDecember 16, 2024 | yahoo.comLyme Regis town councillor John Trevena stand downDecember 11, 2024 | bridportnews.co.ukTrevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowDecember 10, 2024 | zacks.comTrevena appoints new financial chiefNovember 29, 2024 | investing.comTrevena Appoints Katrine Sutton as New CFONovember 27, 2024 | tipranks.comHC Wainwright & Co. Downgrades Trevena (TRVN)November 16, 2024 | msn.comTrevena, Inc. Navigates Financial Challenges and Strategic ChangesNovember 9, 2024 | msn.comChester County biopharm firm's latest layoffs impact its C-suiteNovember 7, 2024 | bizjournals.comTrevena teeters in dangerous territory, terminating CEO and other execs amid strategic reviewNovember 7, 2024 | fiercebiotech.comTrevena Reports Third Quarter 2024 Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comWhy Trevena (TRVN) Stock Is Down 43% TodayOctober 8, 2024 | msn.comTrevena, Inc. Faces Delisting from NasdaqOctober 6, 2024 | msn.comTrevena Announces Receipt of Nasdaq Delisting NotificationOctober 4, 2024 | globenewswire.comLearn to Evaluate (TRVN) using the ChartsSeptember 16, 2024 | news.stocktradersdaily.comTrevena (NASDAQ:TRVN) Stock Quotes, Forecast and News SummarySeptember 12, 2024 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCBP, NMTR, TRVN, and HEPA Company DescriptionsHepion Pharmaceuticals NASDAQ:HEPA$0.04 -0.01 (-27.04%) As of 03:50 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.TC Biopharm NASDAQ:TCBP$0.68 -0.86 (-55.78%) Closing price 03/21/2025Extended Trading$0.68 0.00 (0.00%) As of 03/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.Trevena NASDAQ:TRVN$1.15 +0.03 (+2.22%) As of 05/30/2025 01:12 PM EasternTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
